A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2016
At a glance
- Drugs Binimetinib (Primary) ; Dactolisib (Primary)
- Indications Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 26 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 24 Jul 2012 Additional lead trial investigators and associated centres added as reported by ClinicalTrials.gov.